Needham Reiterates Buy on Absci, Maintains $7 Price Target

3/30/2026
Impact: 70
Healthcare

Needham analyst Gil Blum has reiterated a Buy rating on Absci (NASDAQ: ABSI) and maintained a price target of $7 for the stock.

AI summary, not financial advice

Share: